Want to join the conversation?
World's leading healthcare diagnostics provider $LH launched a new FDA-approved diagnostic test for PD-L1 with expanded approval of $BMY's OPDIVO (nivolumab) treating patients with previously-treated non-small cell lung cancer (NSCLC). $LH's CEO quoted "The launch of this innovative assay reinforces the importance of LabCorp-Covance combination."
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.